RXi Pharmaceuticals Corp. (NASDAQ:RXII) shares dropped 2.9% during trading on Thursday . The company traded as low as $2.33 and last traded at $2.33, with a volume of 50,745 shares traded. The stock had previously closed at $2.40.

RXII has been the topic of a number of research reports. Zacks Investment Research cut RXi Pharmaceuticals Corp. from a “buy” rating to a “hold” rating in a research note on Friday, July 15th. HC Wainwright initiated coverage on RXi Pharmaceuticals Corp. in a research note on Tuesday, June 7th. They set a “buy” rating and a $3.50 price target on the stock.

The stock’s 50 day moving average is $2.37 and its 200 day moving average is $2.47. The company’s market cap is $15.28 million.

RXi Pharmaceuticals Corp. (NASDAQ:RXII) last issued its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. During the same period last year, the company earned ($0.50) EPS. On average, equities analysts anticipate that RXi Pharmaceuticals Corp. will post ($1.40) EPS for the current year.

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.